Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

550 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Exploring Patterns of Mitomycin C Use in Community Practice Urology.
Mossanen M, Ingham MD, Leow JJ, Tinay I, Wang Y, Krasnow RE, Preston MA, Bellmunt J, Chung BI, Rosenberg JE, Chang SL. Mossanen M, et al. Among authors: bellmunt j. Urol Pract. 2018 Jan;5(1):7-14. doi: 10.1016/j.urpr.2017.02.002. Epub 2017 Feb 10. Urol Pract. 2018. PMID: 37300180
Oligometastatic Bladder Cancer: Defining a Novel Entity.
Labaki C, Saad E, Choueiri TK, Bellmunt J. Labaki C, et al. Among authors: bellmunt j. Eur Urol. 2023 Oct;84(4):390-392. doi: 10.1016/j.eururo.2023.06.003. Epub 2023 Jul 5. Eur Urol. 2023. PMID: 37414704 No abstract available.
Re: Martin Swinton, Neethu Billy Graham Mariam, Jean Ling Tan, et al. Bladder-Sparing Treatment with Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients with Clinically Node-positive Nonmetastatic Bladder Cancer. J Clin Oncol. 2023;41:4406-4415.
Seisen T, Rouprêt M, Trinh QD, Bellmunt J. Seisen T, et al. Among authors: bellmunt j. Eur Urol. 2024 Jan;85(1):e19-e21. doi: 10.1016/j.eururo.2023.09.028. Epub 2023 Oct 19. Eur Urol. 2024. PMID: 37865549 No abstract available.
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.
McGregor BA, Sonpavde GP, Kwak L, Regan MM, Gao X, Hvidsten H, Mantia CM, Wei XX, Berchuck JE, Berg SA, Ravi PK, Michaelson MD, Choueiri TK, Bellmunt J. McGregor BA, et al. Among authors: bellmunt j. Ann Oncol. 2024 Jan;35(1):91-97. doi: 10.1016/j.annonc.2023.09.3114. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871703 Free article. Clinical Trial.
550 results